Biomea Fusion Reports Q3 2026 Financials and Updates Clinical Pipeline

Biomea Fusion, Inc. reported its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical trials. As of September 30, 2026, the company held $26.8 million in cash, cash equivalents, and restricted cash. During the three months ended September 30, 2026, the company reported a net loss attributable to common stockholders of $6.2 million, compared to a net loss of $16.4 million for the same period in 2025.

The company reported research and development expenses of $8.5 million for the third quarter of 2026, a decrease of $5.9 million compared to the same period in 2025. General and administrative expenses were $4.4 million for the third quarter of 2026, compared to $4.2 million for the same period in 2025.

In terms of clinical progress, Biomea Fusion announced the completion of enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes. Topline data for this trial is expected in the first quarter of 2027. Additionally, enrollment is ongoing in the Phase II COVALENT-212 trial evaluating icovamenib in patients with type 2 diabetes not achieving glycemic targets on GLP-1 receptor agonist therapy, with topline data expected in the second quarter of 2027.

The company also announced first-in-human results for BMF-650, an investigational next-generation oral GLP-1 receptor agonist. The Phase I GLP-131 clinical trial demonstrated consistent weight reduction across five multiple ascending dose cohorts over four weeks. Across Cohorts 1-4, mean weight reduction ranged from 1.5% to 3.2% at Day 29, compared to 0.1% for pooled placebo. At doses of 200 mg or higher once daily, mean weekly weight reduction was approximately 0.97 kg. BMF-650 was generally well tolerated across all five active-dose cohorts, with all reported treatment-emergent adverse events being mild or moderate.

Biomea Fusion also dosed the first patient in the Open Label Adaptive Platform (OPAL) trial evaluating icovamenib in combination with semaglutide, in collaboration with the University of Leicester. The company projects its cash runway to extend into the second quarter of 2027.